Financial Performance - Pulse Biosciences reported a quarterly loss of $0.26 per share, better than the Zacks Consensus Estimate of a loss of $0.32, representing an earnings surprise of +18.75% [1] - The company posted revenues of $0.26 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 5.60%, compared to zero revenues a year ago [2] - The current consensus EPS estimate for the upcoming quarter is -$0.37 on $0.5 million in revenues, and for the current fiscal year, it is -$1.66 on $3.75 million in revenues [7] Stock Performance - Pulse Biosciences shares have increased by approximately 85.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Instruments industry, to which Pulse Biosciences belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Core Insights - 908 Devices Inc. shares experienced a significant increase of 19.2% to $6.52, following a strong trading volume, contrasting with a 7.8% decline over the previous four weeks [1][2] Financial Performance - The company reported preliminary unaudited financial results for Q4 2025, with revenue reaching $17.2 million, indicating a growth of approximately 20%. This growth was attributed to strong performance in the U.S. state and local channel, increased international adoption of VipIR, and sales to federal and defense customers [2] - The company achieved a positive adjusted EBITDA in the fourth quarter, reflecting operational efficiency [2] Earnings Expectations - For the upcoming report, 908 Devices is expected to post a quarterly loss of $0.06 per share, which represents a year-over-year change of +81.3%. Revenue is anticipated to be $15.84 million, down 15.8% from the same quarter last year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] Industry Context - 908 Devices is part of the Zacks Medical - Instruments industry, where another company, Sight Sciences, Inc., saw a decline of 3.6% in its last trading session and has returned -23.3% over the past month [4] - Sight Sciences' consensus EPS estimate for the upcoming report has also remained unchanged, reflecting a year-over-year change of +26.1% [5]

Core Insights - The Cooper Companies, Inc. (COO) reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.15, an 11% year-over-year increase, surpassing the Zacks Consensus Estimate of $1.11 by 3.6% [1] - Revenues reached $1.065 billion, reflecting a 5% year-over-year increase on a reported basis and a 3% organic growth, also beating the Zacks Consensus Estimate by 0.5% [2] Financial Performance - GAAP EPS for the quarter was 43 cents, down 27% year over year [1] - Adjusted gross profit rose 3.4% to $704.7 million, but adjusted gross margin contracted by almost 70 basis points to 66% due to an unfavorable product mix and tariff headwinds [14] - Selling, general and administrative expenses increased by 7.1% to $419.2 million, while research and development expenses rose by 9.8% to $41.4 million [15] - Adjusted operating profit totaled $288 million, reflecting a 9.4% increase from the previous year, with an adjusted operating margin expanding by 110 basis points to 27% [15] Segment Performance - CooperVision (CVI) segment revenues were $709.6 million, up 5% year over year, driven by MyDay contract wins and strong MiSight sales [4][7] - The CVI segment's Toric and multifocal revenues totaled $344.6 million, up 7% year over year, while Sphere and other revenues reached $365 million, up 3% year over year [8] - The CooperSurgical (CSI) segment's revenues totaled $355.6 million, up 4% year over year, with Office and surgical revenues at $214.6 million, up 6% [11][12] Geographic Performance - Americas' revenues totaled $285.1 million, up 5% year over year, while EMEA revenues amounted to $277.1 million, up 8% year over year [9] - Asia Pacific revenues were $147.4 million, down 1% year over year, primarily due to a 28% decline in China [10] Future Outlook - For fiscal 2026, the company expects revenues in the range of $4,299-$4,338 million, indicating an organic improvement of 3-4% from the prior year [17] - The CVI segment's revenues are projected to be between $2,900-$2,925 million, suggesting an organic improvement of 4.5-5.5% [17] - The CSI segment's revenues are anticipated to be in the range of $1,399-$1,413 million, indicating an organic improvement of 4-5% [18] Growth Catalysts - The company is set to benefit from the global rollout of the MyDay portfolio, expanded private-label wins, and new product launches in 2026 [20] - MiSight is expected to deliver another 20-25% growth, supported by launches in Europe and Japan [20] - The company aims to unlock approximately $50 million in annual savings through AI-driven operational efficiencies [21]

United Acquisition Corp. I As filed with the Securities and Exchange Commission on December 2, 2025. Registration No. 333-_____ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices) Paul Packer Chief Executive Officer 7100 W. Camino Real, Suite 302-48 Boca Raton, Florida 33433 212-847-3248 (Exact Name of Regis ...

Core Insights - Sight Sciences reported strong third-quarter results, raising its revenue guidance for 2025 to $76 million to $78 million, driven by growth in its surgical glaucoma segment and advancements in its dry eye business [4][9][30] - The company is focusing on expanding its Tiered Care franchise, which aims to establish a new category of reimbursed interventional dry eye treatments, following the establishment of fee schedules by First Coast Service Options and Novitas Solutions [8][10][22] Financial Performance - Total revenue for Q3 2025 was $19.9 million, a 1% decrease year-over-year, while surgical glaucoma revenue increased by 6% to $19.7 million [27][28] - Dry eye revenue fell to $200,000 from $1.5 million, aligning with expectations as the company prioritized achieving reimbursed market access for Tiered Care procedures [28] - Gross margin improved to 86%, up from 84%, with surgical glaucoma gross margin remaining stable at 87% [28][29] Market Opportunities - The company estimates approximately 10.4 million Medicare-covered lives in regions where new fee schedules for Tiered Care have been established, indicating a significant market opportunity [10][12] - There are around 6,500 eye care providers identified as potential adopters of Tiered Care procedures, with an existing customer base of about 200 providers who have previously purchased related products [12][13] Strategic Initiatives - The management team is focused on securing additional reimbursement coverage and payment decisions for Tiered Care, accelerating commercial momentum in both surgical glaucoma and dry eye segments, and deepening customer engagement through education initiatives [25][66] - The company has made significant progress in reengaging dormant accounts and expanding its customer base, particularly in the context of the new reimbursement environment for Tiered Care [58][66] Management Changes - Recent management changes include the promotion of Ali Bauerlein to Chief Operating Officer and Jim Rodberg to Chief Financial Officer, aimed at enhancing operational execution and strategic focus [21][23][24]

Core Insights - Steris (STE) reported quarterly earnings of $2.47 per share, exceeding the Zacks Consensus Estimate of $2.38 per share, and up from $2.14 per share a year ago, representing an earnings surprise of +3.78% [1] - The company achieved revenues of $1.46 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.31% and increasing from $1.33 billion year-over-year [2] - Steris shares have increased approximately 17.7% year-to-date, outperforming the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.54, with expected revenues of $1.49 billion, and for the current fiscal year, the EPS estimate is $10.07 on revenues of $5.91 billion [7] - The trend of estimate revisions for Steris was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Steris belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting that companies in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - Sight Sciences, Inc. (SGHT), another company in the same industry, is expected to report a quarterly loss of $0.26 per share, reflecting a year-over-year decline of -18.2%, with revenues anticipated to be $17.16 million, down 14.9% from the previous year [9][10]

Core Insights - Glaukos Corporation (GKOS) is experiencing significant growth, with first-half 2025 revenues reaching $230.8 million, a 27.3% year-over-year increase, primarily driven by the adoption of the iDose TR implant [1][8] - The company has raised its full-year revenue guidance to $480-$486 million, indicating strong commercial momentum [1][8] Near-Term Growth Drivers - The iDose TR launch is gaining traction, generating approximately $31 million in second-quarter sales, with over 80% of volume coming from regions with established reimbursement schedules [3][8] - International glaucoma revenues increased by 20% year-over-year to $31.3 million, supported by the EU MDR clearance for iStent Infinite, which enhances Glaukos' interventional glaucoma strategy [4][8] Long-Term Growth Catalysts - Glaukos is advancing a diversified pipeline across five therapeutic platforms, with pivotal trials for iStent Infinite and PRESERFLO MicroShunt underway, and Epioxa awaiting FDA approval by October 2025 [9][10] - The company is positioning itself in a new stand-alone interventional glaucoma market, with expectations of millions of procedures annually over the next decade [10][11] Challenges and Watchpoints - Reimbursement complexities, including MAC LCD restrictions, pose challenges, although iDose TR reimbursement is expanding [12][14] - Execution risk exists in scaling iDose TR, particularly in regions with slower adoption rates [13][14] - Corneal health sales showed only a 4% year-over-year increase, with anticipated revenue softness during the transition to Epioxa [15][16] Competitive Landscape - The iDose TR launch positions Glaukos favorably against competitors like Alcon, Johnson & Johnson, and Sight Sciences, although Glaukos shares have underperformed compared to these rivals [17][18][21]

Company Performance - Veracyte reported quarterly earnings of $0.44 per share, exceeding the Zacks Consensus Estimate of $0.31 per share, and up from $0.30 per share a year ago, representing an earnings surprise of +41.94% [1] - The company achieved revenues of $130.16 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.06%, compared to $114.43 million in the same quarter last year [2] - Over the last four quarters, Veracyte has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance - Veracyte shares have declined approximately 36.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current Zacks Rank for Veracyte is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.33 on revenues of $125.73 million, and for the current fiscal year, it is $1.32 on revenues of $493.72 million [7] - The outlook for the Medical - Instruments industry, where Veracyte operates, is currently in the bottom 41% of over 250 Zacks industries, which may impact the stock's performance [8]

Core Insights - Glaukos Corporation (GKOS) reported a record-breaking first-quarter 2025 performance with revenues of $106.7 million, a 25% year-over-year increase, primarily driven by the adoption of the iDose TR implant [1][8] - The company reaffirmed its full-year revenue guidance of $475-$485 million, indicating confidence in its commercial momentum [1] Near-Term Growth Drivers - The iDose TR launch is gaining traction, with U.S. glaucoma sales increasing by 41% year-over-year, contributing nearly $21 million in the first quarter, reflecting an $85 million annualized run rate [3] - Internationally, Glaukos achieved $29 million in interventional glaucoma sales, a 15% year-over-year increase, supported by the growing acceptance of minimally invasive glaucoma surgery (MIGS) [4] Long-Term Growth Catalysts - Glaukos has a robust R&D pipeline with key programs including Epioxa, iDose Trex, PRESERFLO MicroShunt, and GLK-401, which are expected to broaden the company's addressable market in the next three to five years [5][6] - The company is cultivating standalone use of MIGS devices like iStent infinite, anticipating long-term growth as more surgeons adopt interventional glaucoma practices [7] Challenges and Watchpoints - Reimbursement complexities and LCD restrictions are impacting legacy stent sales, which declined mid-single digits in the first quarter, with expectations of continued pressure through 2025 [8][9] - Sales of Photrexa remain muted due to the Medicaid Drug Rebate Program, with near-term growth in this segment expected to be flat to low-single digits [10] Competitive Landscape - The iDose TR launch positions Glaukos ahead in procedural glaucoma drug delivery, but competition from Alcon, Johnson & Johnson, and Sight Sciences remains significant [11] - Year-to-date, Glaukos shares have declined by 31.7%, underperforming its rivals in the MIGS space, while Alcon and J&J have seen increases [12]

Core Insights - Sight Sciences, Inc. has published its second annual Sustainability Report, emphasizing its commitment to corporate sustainability and enhanced disclosures, including emissions reporting [2][6] Environmental Initiatives - The report details the company's efforts to reduce its environmental footprint through energy efficiency, waste reduction, and sustainable practices, including emissions reporting [3][8] - In 2024, the company reported Scope 1 emissions of 7,655 kg CO₂ and Scope 2 emissions of 32,125 kg CO₂, along with a subset of Scope 3 emissions totaling 2,169,524 kg CO₂ [8] Social Responsibility - The report provides insights into initiatives supporting community engagement, diversity, equity, and inclusion, as well as employee well-being [4] - Voluntary staff turnover decreased to 14% in 2024 from 19% in 2023, and over 50% of the workforce is comprised of women [8] - The company expanded its Women in Leadership initiative and increased the percentage of women in management positions to over 39% as of December 31, 2024, up from 37% in 2023 [8] Governance Practices - The report discloses the company's governance framework, ethical standards, and commitment to transparency and accountability, including information security breach reporting [5][8]